- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03527563
Study on Internet Medical Models for the Management of Patients With Hypertension in China
A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients With Hypertension in China
Обзор исследования
Подробное описание
Protocol Title:A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients with Hypertension in China Study Indication:Hypertension Number of Site:16sites Study Duration (from the initiation of the first site to the end of the follow-up for the last subject): 12 months Duration of Treatment and Management: 6 months Planned Number of Subjects:958 subjects, 479 in each group(blood pressure management in Internet medical model, Conventional medical model) Internet Medical Model:Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
Conventional Medical Model:Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
Inclusion Criteria:
- Male or female, 45 to 75 years old (including 45and 75 years);
- Two measurements of resting systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg on different days during screening;
Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:
- Oral contraceptive, either combined or progestogen alone.
- Injectable progestogen.
- Implants of levonorgestrel.
- Oestrogenic vaginal ring.
- Percutaneous contraceptive patches.
- Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.
- Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
- Subjects who can understand and perform home blood pressure monitoring as required by the study;
- Subjects who voluntarily participate in the study and sign informed consent form.
Exclusion Criteria:
- Two measurements of resting systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg on different days during screening;
- Subjects with the history of cerebral stroke within 6 months prior to screening;
- Subjects with the history of myocardial infarction within 6 months prior to screening;
- Subjects with the history of heart failure;
- Subjects with the history of atrial fibrillation;
- Subjects with the history of coronary artery revascularization;
- Subjects with other serious diseases, such as tumor;
- Subjects diagnosed as the secondary hypertension;
- Subjects with congenital or acquired organic heart disease;
- Pregnant or lactant subjects;
- Subjects with severe mental disease;
- Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or creatinine > 2X upper limit value
- Subjects who were previously diagnosed with diabetes that is currently poorly controlled: FBG>10mmol/L;
- Subjects who are unable to conduct blood pressure self-test;
- The subject has any other known condition at screening that would compromise subject safety, might affect life expectancy, or making it difficult to successfully manage and follow the subject according to the protocol.
Efficacy Evaluations:
Primary Efficacy Endpoints:
- Blood pressure control rate of subjects in the two groups at Month 6 Secondary Efficacy Endpoints:
- Blood pressure control rate of subjects in the two groups at Month 3
- Blood pressure value of subjects in the two groups at Month 3 and Month 6
- Change of blood pressure of subjects in the two groups at Month 3 and Month 6
- Variability of blood pressure of subjects in the two groups at Month 3 and Month 6
- Treatment compliance of subjects in the two groups at Month 3 and Month 6
- Medical expense of subjects in the two groups at Month 3 and Month 6
- Treatment satisfaction of subjects in the two groups at Month 3 and Month 6
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Непригодный
Контакты и местонахождение
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Male or female, 45 to 75 years old (including 45 and 75 years);
- Two measurements of resting systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg on different days during screening;
Female subjects of child-bearing potential who are willing to adopt one of the following methods for contraception during the study:
Oral contraceptive, either combined or progestogen alone. Injectable progestogen. Implants of levonorgestrel. Oestrogenic vaginal ring. Percutaneous contraceptive patches. Intrauterine device or intrauterine system showing that the expected failure rate is less than 1% per year as stated in the product label.
Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository).
- Subjects who can understand and perform home blood pressure monitoring as required by the study;
- Subjects who voluntarily participate in the study and sign informed consent form.
Exclusion Criteria:
- Two measurements of resting systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥110mmHg on different days during screening;
- Subjects with the history of cerebral stroke within 6 months prior to screening;
- Subjects with the history of myocardial infarction within 6 months prior to screening;
- Subjects with the history of heart failure;
- Subjects with the history of atrial fibrillation;
- Subjects with the history of coronary artery revascularization;
- Subjects with other serious diseases, such as tumor;
- Subjects diagnosed as the secondary hypertension;
- Subjects with congenital or acquired organic heart disease;
- Pregnant or lactant subjects;
- Subjects with severe mental disease;
- Subjects with abnormal liver and renal function: ALT or AST>2 X upper limit value; Or creatinine >2 X upper limit value;
- Subjects who were previously diagnosed with diabetes that is currently poorly controlled: FBG>10mmol/L;
- Subjects who are unable to conduct blood pressure self-test;
- The subject has any other known condition at screening that would compromise subject safety, might affect life expectancy, or making it difficult to successfully manage and follow the subject according to the protocol.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Другой
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Другой: Internet Medical Model
Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
|
Subjects in the Internet group should upload blood pressure monitoring data at least once per day.
It is highly recommended to upload two pressure monitoring results to capture more blood pressure information.
The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg.
After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician.
Then the frequency of communication will be changed to once a month.
Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
|
Без вмешательства: Conventional Medical Model
Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Primary endpoint: blood pressure control rate of subjects in the two groups at Month 6
Временное ограничение: 6 months
|
Definition of blood pressure control rate is that the percent of subjects with systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg
|
6 months
|
Соавторы и исследователи
Спонсор
Соавторы
Публикации и полезные ссылки
Общие публикации
- Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D; American Heart Association; American Society of Hypertension; Preventive Cardiovascular Nurses Association. Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. J Cardiovasc Nurs. 2008 Jul-Aug;23(4):299-323. doi: 10.1097/01.JCN.0000317429.98844.04.
- Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008 May 3;371(9623):1513-8. doi: 10.1016/S0140-6736(08)60655-8.
Даты записи исследования
Изучение основных дат
Начало исследования (Ожидаемый)
Первичное завершение (Ожидаемый)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Internet Medical Model
-
Mercy ResearchЗавершенныйСептический шок | Тяжелый сепсис | МикроциркуляцияСоединенные Штаты
-
Edwards LifesciencesЗавершенныйИшемическая болезнь сердца | Сердечная недостаточность | Стеноз аортального клапана | Недостаточность аортального клапана | Заболевание аортального клапанаКанада, Соединенные Штаты, Австрия, Германия, Испания, Соединенное Королевство
-
Boston Scientific CorporationЗавершенныйЭндоскопическая ретроградная холангиопанкреатографияСоединенные Штаты, Франция, Гонконг, Сингапур, Австралия, Канада, Германия, Индия, Италия, Нидерланды, Южная Африка
-
InSightecРекрутингГлиома | Глиобластома | Жидкая биопсияСоединенные Штаты, Канада
-
Boston Scientific CorporationЗавершенныйЭндоскопическая ретроградная холангиопанкреатографияСоединенные Штаты, Нидерланды
-
Mayo ClinicEli Lilly and CompanyЗавершенный
-
Boston Scientific CorporationЗавершенныйЭндоскопическая ретроградная холангиопанкреатографияСоединенные Штаты
-
Edwards LifesciencesЗавершенный
-
ivWatch, LLCЗавершенныйИнфильтрация периферической внутривенной терапииСоединенные Штаты
-
Kaiser PermanenteOregon Health and Science UniversityЗавершенный